LT3103453T - Vaisto kompozicija, apimanti diamino heterociklinį karboksamido junginį kaip aktyvų ingredientą - Google Patents

Vaisto kompozicija, apimanti diamino heterociklinį karboksamido junginį kaip aktyvų ingredientą

Info

Publication number
LT3103453T
LT3103453T LTEP15746276.3T LT15746276T LT3103453T LT 3103453 T LT3103453 T LT 3103453T LT 15746276 T LT15746276 T LT 15746276T LT 3103453 T LT3103453 T LT 3103453T
Authority
LT
Lithuania
Prior art keywords
active ingredient
medicinal composition
carboxamide compound
heterocyclic carboxamide
diamino heterocyclic
Prior art date
Application number
LTEP15746276.3T
Other languages
English (en)
Inventor
Tomohiro Eguchi
Masamichi Mori
Yoko Yamaki
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of LT3103453T publication Critical patent/LT3103453T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP15746276.3T 2014-02-04 2015-02-03 Vaisto kompozicija, apimanti diamino heterociklinį karboksamido junginį kaip aktyvų ingredientą LT3103453T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014019226 2014-02-04
PCT/JP2015/053018 WO2015119122A1 (ja) 2014-02-04 2015-02-03 ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
LT3103453T true LT3103453T (lt) 2020-05-11

Family

ID=53777926

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15746276.3T LT3103453T (lt) 2014-02-04 2015-02-03 Vaisto kompozicija, apimanti diamino heterociklinį karboksamido junginį kaip aktyvų ingredientą

Country Status (29)

Country Link
US (2) US11045468B2 (lt)
EP (1) EP3103453B1 (lt)
JP (1) JP6390626B2 (lt)
KR (1) KR102322338B1 (lt)
CN (3) CN105939714A (lt)
AU (1) AU2015215578B2 (lt)
BR (1) BR112016017897A8 (lt)
CA (1) CA2938818C (lt)
CY (1) CY1122968T1 (lt)
DK (1) DK3103453T3 (lt)
EA (1) EA033304B1 (lt)
ES (1) ES2788390T3 (lt)
HR (1) HRP20200662T1 (lt)
HU (1) HUE049437T2 (lt)
IL (1) IL247077B (lt)
LT (1) LT3103453T (lt)
ME (1) ME03775B (lt)
MX (1) MX363543B (lt)
MY (1) MY193536A (lt)
PH (1) PH12016501527A1 (lt)
PL (1) PL3103453T3 (lt)
PT (1) PT3103453T (lt)
RS (1) RS60150B1 (lt)
SG (1) SG11201606413RA (lt)
SI (1) SI3103453T1 (lt)
TW (1) TWI655945B (lt)
UA (1) UA120607C2 (lt)
WO (1) WO2015119122A1 (lt)
ZA (1) ZA201605379B (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102322338B1 (ko) * 2014-02-04 2021-11-05 아스텔라스세이야쿠 가부시키가이샤 디아미노헤테로환 카르복스아미드 화합물을 유효 성분으로 하는 의약 조성물
JP6132294B1 (ja) 2015-07-03 2017-05-24 アステラス製薬株式会社 安定な経口投与用医薬組成物
US10744134B2 (en) 2015-11-04 2020-08-18 Astellas Pharma Inc. Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JPWO2022220227A1 (lt) * 2021-04-14 2022-10-20
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2255190A4 (en) * 2008-02-12 2011-05-04 Brigham & Womens Hospital FISH TEST FOR EML4-ALK FUSION IN LUNG CANCER
MX2010010272A (es) * 2008-03-19 2011-05-25 Chembridge Corp Nuevos inhibidores de tirosina quinasa.
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
BRPI1011838B8 (pt) * 2009-05-08 2021-05-25 Astellas Pharma Inc compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
SG11201402343SA (en) * 2011-11-21 2014-06-27 Immunogen Inc Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
UA113204C2 (xx) * 2012-04-02 2016-12-26 Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції
RS58192B1 (sr) * 2012-11-21 2019-03-29 Janssen Biotech Inc Bispecifična egfr/c-met antitela
KR102322338B1 (ko) * 2014-02-04 2021-11-05 아스텔라스세이야쿠 가부시키가이샤 디아미노헤테로환 카르복스아미드 화합물을 유효 성분으로 하는 의약 조성물
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
JP6132294B1 (ja) * 2015-07-03 2017-05-24 アステラス製薬株式会社 安定な経口投与用医薬組成物

Also Published As

Publication number Publication date
PL3103453T3 (pl) 2020-06-29
PH12016501527B1 (en) 2017-02-06
RS60150B1 (sr) 2020-05-29
IL247077B (en) 2020-08-31
MX363543B (es) 2019-03-27
ME03775B (me) 2021-04-20
US20210290618A1 (en) 2021-09-23
NZ722750A (en) 2020-11-27
AU2015215578B2 (en) 2019-07-11
IL247077A0 (en) 2016-09-29
UA120607C2 (uk) 2020-01-10
JP6390626B2 (ja) 2018-09-19
SI3103453T1 (sl) 2020-10-30
AU2015215578A1 (en) 2016-08-18
PH12016501527A1 (en) 2017-02-06
CN105939714A (zh) 2016-09-14
DK3103453T3 (da) 2020-04-20
CY1122968T1 (el) 2021-10-29
ZA201605379B (en) 2018-05-30
CA2938818A1 (en) 2015-08-13
CN113425727A (zh) 2021-09-24
HRP20200662T1 (hr) 2020-10-02
US11045468B2 (en) 2021-06-29
CN116509866A (zh) 2023-08-01
US11925638B2 (en) 2024-03-12
WO2015119122A1 (ja) 2015-08-13
EP3103453B1 (en) 2020-04-01
JPWO2015119122A1 (ja) 2017-03-23
MX2016010134A (es) 2016-10-07
KR102322338B1 (ko) 2021-11-05
AU2015215578A2 (en) 2016-10-20
US20160339020A1 (en) 2016-11-24
TW201613594A (en) 2016-04-16
CA2938818C (en) 2023-03-07
EP3103453A1 (en) 2016-12-14
HUE049437T2 (hu) 2020-09-28
EA201691570A1 (ru) 2016-11-30
EP3103453A4 (en) 2017-09-06
TWI655945B (zh) 2019-04-11
EA033304B1 (ru) 2019-09-30
ES2788390T3 (es) 2020-10-21
MY193536A (en) 2022-10-18
KR20160110498A (ko) 2016-09-21
SG11201606413RA (en) 2016-09-29
BR112016017897A8 (pt) 2020-06-30
PT3103453T (pt) 2020-05-06

Similar Documents

Publication Publication Date Title
HK1219432A1 (zh) 以嘧啶化合物爲有效成分的醫藥組合物
IL247062A0 (en) Heterocyclic compounds, their preparation and pharmaceutical preparations containing them
ZA201605379B (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
IL253538B (en) Heterocyclic compound and pharmaceutical compound containing it
IL248090A0 (en) Solid pharmaceutical preparations containing biopterin derivatives and their uses
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
PT3202759T (pt) Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
IL304109A (en) Pharmaceutical preparations containing spinamide
HK1243927A1 (zh) 含有茶皂醇衍生物作爲活性成分的組合物
IL249010A0 (en) A pharmaceutical preparation containing a pyrazine carboxamide compound as an active ingredient
SG11201610636VA (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
PL3313370T3 (pl) Okulistyczna kompozycja farmaceutyczna
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
EP3372231A4 (en) PHARMACEUTICAL COMPOSITION FOR ANTICANCER IMMUNOTHERAPY AND / OR FOR IMMUNOSTIMULATION, CONTAINING AS ACTIVE PRINCIPLE A HETEROCYCLIC DIAMINO CARBOXAMIDE COMPOUND
IL252663A0 (en) A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient
EP3120848A4 (en) Therapeutic/preventive agent containing coumarin derivative as active ingredient
IL252664A0 (en) A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient
PT3558261T (pt) Composições farmacêuticas compreendendo safinamida